Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Acura Pharmaceuticals, Inc.
Type
Public
Traded as NASDAQ:ACUR
Industry Pharmaceutical industry
Founded 1935
Headquarters Palatine, Illinois
Products Pharmaceuticals
Revenue Increase US$ .75 million (2015)
Website acurapharm.com

Acura Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of deterrents to medication abuse and misuse. As of 2012, the company had several opioid products under development, which would use "Aversion Technology". As of 2014, the company was a publicly traded company, listed on NASDAQ under the symbol "ACUR".

In 2013, the Company settled Oxecta patent litigation with Impax Laboratories (IPXL) and Par Pharmaceutical.

Aversion Technology, provides abuse deterrent benefits to orally administered pharmaceutical drugs. Many of the products approved by the US Food and Drug Administration, such as OXECTA from Pfizer, have incorporated such technology.

Impede Technology is used in easily dissolved tablets and involves the addition of an inactive ingredient polymer matrix, which has been shown to form a thick gel and start a conversion process of crushed pseudoephedrine (PSE). This technology the aims of the Combat Methamphetamine Epidemic Act enacted in the United States in 2006.

The company has an agreement to license, develop and commercialize opioid analgesic products with King Pharmaceuticals.

In 2013, multiple retailers – including Kroger and Fruth Pharmacy – stocked Acura's product Nexafed, which is a drug that attempts to prevent illicit methamphetamine synthesis by incorporating the new pseudoephedrine conversion technology from the company. Nexafed has blocker in it that stops the making of methamphetamine.

Investment goal date:
Dividends reinvested
Acura Pharmaceuticals, Inc. ACUR report Q2 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q4 2017
2018-02-14
--
--
Q3 2017
2017-11-13
--
--
Q2 2017
2017-08-14
0.0000
-0.1800
Q1 2017
2017-05-12
0.0000
0.0300
Q4 2016
2017-03-31
0.0000
0.1300
Q3 2016
2016-11-14
0.0000
-0.1900
Q2 2016
2016-08-08
0.0000
-0.2800
Q1 2016
2016-05-02
0.0000
-0.2800
Q4 2015
2016-02-29
0.0000
-0.0800
Q3 2015
2015-11-04
0.0000
-0.2300
Q2 2015
2015-08-03
0.0000
-0.2500
Q1 2015
2015-05-04
0.0000
0.1500
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Major Shareholders
Name Relationship
Total Shares
Holding stocks
CLAUDIUS LLC
22.4800% (10978674)
ACUR /
CLEMENS PETER A
0.5600% (275918)
ACUR /
WESSON BRUCE F
0.1200% (58670)
ACUR / DSCI / MDAS /
SKELLY WILLIAM G
0.0600% (28345)
ACUR /
ROSS GEORGE K
0.0200% (11565)
ACUR /
EMIGH JAMES F
0.4100% (198304)
ACUR /
CARE CAPITAL II LLC
8.3100% (4058337)
ACUR /
THANGARAJ IMMANUEL
0.0500% (23812)
ACUR /
Seiser Robert A
0.0500% (23311)
ACUR /
Jones Robert B
0.1300% (62778)
ACUR /
% ()